A. N. Tsygin

A. N. Tsygin

Auto-generated profile, based on publicly available information

A. N. Tsygin

Federal State Autonomous Institution “National Medical Research Center of Children’s Health” of the Ministry of Health of the Russian Federation, 119991 Moscow, Russia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AMAnastasiia Milovanova
Anastasiia Milovanova
PAPetr Ananin
Petr Ananin
TVTatiana Vashurina
Tatiana Vashurina
OZOlga Zrobok
Olga Zrobok
SDSvetlana Dmitrienko
Svetlana Dmitrienko
TATsygin Alexey
Tsygin Alexey
Schimke immuno-osseous dysplasia (SIOD) is a hereditary autosomal-recessive multi-system disorder with early mortality. It has variable clinical presentations, mainly characterised by disproportional short stature, steroid-resistant nephrotic syndrome, spondyloepiphyseal dysplasia, and T-cell immunodeficiency. In the majority of cases, SIOD is caused by pathogenic sequence variants (PSVs) in the SMARCAL1 gene that encodes protein involved in chromatin remodelling. SIOD is an ultra-rare condition, with an incidence of ~1 per 1–3 million live births; data on its genetic and clinical features are scarce. We conducted a retrospective study of 21 paediatric patients with SIOD diagnosed in our centre during the years 2003–2023. The most common extra-renal clinical features were short stature, osseous dysplasia, multiple stigmas, and leukopenia. Proteinuria of varying severity was observed in 16 cases. The five-year overall survival rate (OS) was 89% (95% CI 77–100%), and the ten-year OS was 10%. Next-generation sequencing (NGS) revealed the following PSVs in SMARCAL1 in 19 patients: c.355_500del, c.2542G>T, c.2290C>T, c.2562del, c.2533_2534del, c.1582A>C, c.1933C>T, c.1010T>C, c.1736C>T, c.2070dup, c.2551A>T, c.2149_2150dup, c.939delC, and c.1451T>A; the most common was c.2542G>T, resulting in premature translation termination (p.E848*), and it was found in 14 patients either in a homozygous (four patients) or compound-heterozygous (10 patients) state. According to microsatellite analysis, it is a “founder mutation” in Russia.

30 April 2019 in Russian Pediatric Journal
Verified
Journal Article
Open access
PAPetr Ananin
Petr Ananin
OKO. V. Komarova
O. V. Komarova
TVT. V. Vashurina
T. V. Vashurina
OZO. I. Zrobok
O. I. Zrobok
ETE. N. Tsygina
E. N. Tsygina
ATA. N. Tsygin
A. N. Tsygin
Background: Hypophosphatemic rickets is a rare disease, related to renal phosphate waste, which cause bone deformities, and lead to walking abnormalities and to the reduction in the quality of life. Clinical recommendations in different countries vary in medications, recommended doses and surgery approach. The main aim was to analyze phosphate metabolism in children with hypophosphatemic rickets and to evaluate results of conservative and surgical therapy. Methods: We analyzed medical histories of 15 children with hypophosphatemic rickets and investigated phosphate metabolism, including the measurement of serum intact fibroblast growth factor 23 and X-ray bone densitometry. Routine biochemical tests were assessed with our laboratory reference data, the level of iFGF-23 in hypophosphatemic children was compared with the same values in 18 healthy children. Results: We investigated 15 girls with hypophosphatemic rickets, aged of from 3 years 9 months to 18 years 7 months. All children were treated with alphacalcidol and inorganic phosphate (in dose from 16.21 to 103.3 mg/kg, during from 1 to 114 months). Eleven (73%) children had surgical correction of bone deformations, starting at the age of from 3 to 12 years. Ten (91%) of them had the relapse of bone deformations. Two of four children undergone to the correction of bone abnormalities on alphacalcidol and phosphate therapy without surgery. The level of iFGF-23 in children with hypophosphatemic rickets was 73.11 pg/ml, and exceed iFGF-23 in control group (22.92 pg/ml), p =0,009. Conclusion: Early surgical treatment of bone deformations is not indicated in hypophosphatemic rickets because of risk of recurrence, observed in 91% of our patients. There could be spontaneous correction of bone deformation during conservative therapy, when it is started early.